High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

Abstract Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has n...

Full description

Bibliographic Details
Main Authors: Yinzong Xiao, Lunquan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xue-Gong Fan
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Cancer
Subjects:
HCC
HMGB1
Sorafenib resistance
Mitochondria
Online Access:http://link.springer.com/article/10.1186/s12885-017-3868-2

Internet

http://link.springer.com/article/10.1186/s12885-017-3868-2

Similar Items